Equities research analysts expect that Five Prime Therapeutics, Inc. (NASDAQ:FPRX) will report earnings per share of ($1.32) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Five Prime Therapeutics’ earnings, with estimates ranging from ($1.50) to ($1.01). Five Prime Therapeutics posted earnings per share of ($0.72) during the same quarter last year, which indicates a negative year-over-year growth rate of 83.3%. The business is scheduled to issue its next quarterly earnings report on Thursday, November 2nd.

On average, analysts expect that Five Prime Therapeutics will report full-year earnings of ($5.34) per share for the current fiscal year, with EPS estimates ranging from ($5.78) to ($4.85). For the next financial year, analysts anticipate that the firm will post earnings of ($5.41) per share, with EPS estimates ranging from ($6.41) to ($3.53). Zacks Investment Research’s earnings per share averages are an average based on a survey of research firms that follow Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($1.58) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.15) by $0.43. Five Prime Therapeutics had a negative return on equity of 31.78% and a negative net margin of 356.39%. The company had revenue of $7.80 million during the quarter, compared to analysts’ expectations of $8.32 million. During the same period in the prior year, the business posted ($0.49) earnings per share. The company’s revenue for the quarter was down 16.1% on a year-over-year basis.

A number of research analysts have weighed in on the stock. Jefferies Group LLC reissued a “buy” rating and set a $55.00 target price on shares of Five Prime Therapeutics in a research note on Thursday, June 8th. BidaskClub lowered shares of Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, August 2nd. Finally, ValuEngine raised shares of Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Five Prime Therapeutics has a consensus rating of “Hold” and a consensus price target of $60.80.

ILLEGAL ACTIVITY WARNING: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/11/analysts-expect-five-prime-therapeutics-inc-fprx-to-announce-1-32-eps.html.

Five Prime Therapeutics (NASDAQ FPRX) traded up 6.59% during midday trading on Monday, hitting $36.06. 206,746 shares of the stock traded hands. The firm’s 50-day moving average is $29.95 and its 200-day moving average is $32.52. The company’s market cap is $1.01 billion. Five Prime Therapeutics has a 52-week low of $25.97 and a 52-week high of $60.98.

Several institutional investors and hedge funds have recently modified their holdings of FPRX. Nationwide Fund Advisors boosted its stake in shares of Five Prime Therapeutics by 3.1% during the first quarter. Nationwide Fund Advisors now owns 59,400 shares of the biotechnology company’s stock valued at $2,147,000 after purchasing an additional 1,771 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Five Prime Therapeutics by 19.1% during the first quarter. Wells Fargo & Company MN now owns 185,266 shares of the biotechnology company’s stock valued at $6,697,000 after purchasing an additional 29,701 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Five Prime Therapeutics by 7.0% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,030 shares of the biotechnology company’s stock valued at $724,000 after purchasing an additional 1,302 shares during the period. Virginia Retirement Systems ET AL boosted its stake in shares of Five Prime Therapeutics by 50.9% during the first quarter. Virginia Retirement Systems ET AL now owns 40,300 shares of the biotechnology company’s stock valued at $1,457,000 after purchasing an additional 13,600 shares during the period. Finally, Trexquant Investment LP purchased a new stake in shares of Five Prime Therapeutics during the first quarter valued at $784,000. 84.08% of the stock is owned by hedge funds and other institutional investors.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related stocks with our FREE daily email newsletter.